OpusDuo(TM) AquaLite(TM) Offers Only Dual System for Laser Dentistry
YOKNEAM, Israel, Oct. 7 - Lumenis Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that its next generation laser system for dental and oral surgical applications, the OpusDuo(TM) AquaLite(TM), will be demonstrated and released for sale at the American Dental Association convention in Philadelphia, Pennsylvania which began October 6, 2005.
Avner Raz, Lumenis' President and CEO, stated, "The next-generation technology of OpusDuo AquaLite improves upon our previous dual-wavelength dental platforms, such as the Opus20(TM) introduced in 2000 and the OpusDuo(TM) introduced in 2002. Our new AquaLite system incorporates extensive market research, product testing and customer feedback, with the most advanced dental laser technology. The AquaLite demonstrates our commitment to the dental market and confidence in this market's growth potential."
The new OpusDuo AquaLite is dentistry's only combination Er:YAG / CO2 dual-wavelength laser system. Its improved technology is predicated on the industry's first dual-wavelength laser and specifically designed for both hard- and soft-tissue procedures. AquaLite includes several unique and customer-defined features, such as the newly introduced illuminated contra- angle handpiece, touch screen control with pre-set operating parameters for 108 hard- and soft-tissue procedures, and several improvements that make the system simple to use. This new product launch follows Lumenis' recent and industry-leading FDA clearance for contact cutting of bone tissue.
"There is no finer system on the market for practitioners who understand laser physics and wish to perform hard- and soft-tissue laser dentistry, or oral and maxillofacial surgery," stated Dr. Robert Strauss of the Medical College of Virginia. "The AquaLite allows practitioners to see the operating field much better, ablate tissue much faster, and work without interruption -- like no other system allows. This is one of the most impressive systems I have worked with in my 20 years of laser experience."
Interested practitioners will be able to perform hands-on demonstrations with Lumenis' OpusDuo AquaLite system at the ADA 2005 Convention in Philadelphia, Pennsylvania, in booth 1439 through October 9th.
About Lumenis
Lumenis is a global developer, manufacturer and seller of laser and light- based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto http://www.lumenis.com
Investors:
Lauri Hanover 1-866-232-6803
972-4-959-9122
The statements in this press release that are not historical facts are forward-looking statements which are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of our Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation (including the Wells Notice recently received in which the staff indicated its intention to recommend that a civil proceeding be brought seeking, among other things, injunctive relief and civil monetary penalties) and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company's continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
